Abstract
Purpose: To investigate the effects of rosuvastatin and benazepril on matrix metalloproteinase-2 (MMP-2), MMP-9 and leukotriene B4 (LTB4) of patients with acute myocardial infarction (AMI).
 Methods: Fifty-six patients with AMI were selected. They were randomly divided into control and study groups. Thirty healthy people were used in the normal group. On the basis of conventional therapy, patients in the control group were given rosuvastatin orally, while those in the study group received rosuvastatin and benazepril orally. The duration of treatment in both groups was 3 months. Serum levels of MMP-2, MMP-9 and LTB4, and incidence of left ventricular remodelling and recurrence of cardiovascular events were determined before and after treatment for both groups.
 Results: MMP-2, MMP-9 and LTB4 levels in serum were significantly lower for the two groups after treatment, when compared to pre-treatment values, and significantly lower in the study group (p < 0.05). Left ventricular remodelling was lower in the study group than in the control group (p < 0.05). Recurrence of cardiovascular events declined significantly in the study group, relative to control (p > 0.05).
 Conclusion: Rosuvastatin and benazepril significantly reduce serum levels of MMP-2, MMP-9 and LTB4 in AMI patients, and thus can potentially prevent ventricular remodelling, improve prognosis and reduce recurrence rate.
Highlights
Acute myocardial infarction (AMI) is based on the formation of coronary atherosclerotic plaques
Research has shown that rosuvastatin can effectively reduce the incidence of left ventricular remodelling after MI, and it could reduce the risk of MI, delay the progression of heart failure and reduce cardiovascular mortality [11]
Studies have shown that heart failure caused by coronary heart disease in patients with exhausted myocardial cells was associated with increased expression of matrix metalloproteinases (MMPs)-9, and that benazepril significantly inhibited MMP-9 expression [13]
Summary
Acute myocardial infarction (AMI) is based on the formation of coronary atherosclerotic plaques. Emotional and other factors cause intravascular plaque rupture and platelet aggregation around the plaque, resulting in coronary artery ischaemia and hypoxia that lead to myocardial necrosis [1]. The incidence, mortality and recurrence of AMI are relatively high, with approximately 500,000 AMI patients in China each year [2]. Leukotriene B4 (LTB4) is involved in the formation of atherosclerotic plaques, and matrix metalloproteinases (MMPs) are associated with plaque instability. Leukotriene B4 (LTB4) affects the expressions of MMPs in arterial plaques, resulting in the instability of atherosclerotic plaque [4]. Relative to other statin drugs, rosuvastatin has the advantages of high safety, few side effects and flexible administration time. Rosuvastatin and benazepril were used to treat patients with AMI. This study received approval from the Ethical Committee of The 4th People’s Hospital of Shenyang (Approval No 4phs-201503221), and was executed in line with the Helsinki declaration of 1964 which was subjected to amendment in 1996 [6]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
